Skip to main content
45°
Cloudy
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
League of Women Voters SRI
League of Women Voters WS
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Jaguar Health, Inc.
< Previous
1
2
3
Next >
Orphan Drug Designation Application Submitted by Jaguar Health Subsidiary for Crofelemer for Short Bowel Syndrome with Intestinal Failure Accepted for Review by European Medicines Agency
September 15, 2021
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Tickers
JAGX
Jaguar Health Announces Closing of Private Placement Priced at a Premium to Market
September 14, 2021
From
Jaguar Health, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
Legal
Product Safety
Regulatory
Tickers
JAGX
Jaguar Health Appoints Karen Brunke, Ph.D. as Corporate and Business Development EVP and Chip Whitlow as Animal Health Products Marketing Director
September 09, 2021
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Tickers
JAGX
Jaguar Health, Inc. Announces 1-for-3 Reverse Stock Split
September 03, 2021
From
Jaguar Health, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
Legal
Product Safety
Regulatory
Tickers
JAGX
Jaguar Health Reports Voting Results from 2021 Annual Meeting of Stockholders
September 03, 2021
From
Jaguar Health, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
Legal
Product Safety
Regulatory
Tickers
JAGX
Jaguar Health Subsidiary Napo Pharmaceuticals Submits Late-Breaking Abstract for Consideration for Presentation at the 2021 IDWeek Annual Meeting
August 23, 2021
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Tickers
JAGX
Jaguar Health Subsidiary Napo Pharmaceuticals Signs License Agreement with its Italian Subsidiary, Napo EU S.p.A., to Develop and Commercialize Crofelemer and Lechlemer in Europe
August 19, 2021
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Tickers
JAGX
Jaguar Health Subsidiary Announces Completion of Additional Preclinical Study of Lechlemer (NP-300), the Company's Human Drug Product Candidate for Diarrhea Relief from Cholera and Other Acute Infectious Diarrhea
August 17, 2021
From
Jaguar Health, Inc.
Via
AccessWire
Topics
Death
Exposures
Death
Product Safety
Tickers
JAGX
Jaguar Health, Inc. Reports 2021 Second Quarter Financial Results
August 13, 2021
From
Jaguar Health, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
COVID-19
Legal
Product Safety
Tickers
JAGX
Jaguar Health Announces Time Change for Friday, August 13th Investor Webcast to 8:00 AM Eastern Time
August 10, 2021
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Tickers
JAGX
Jaguar Health to Host Investor Webcast Friday, August 13th at 8:30 AM Eastern Time Regarding Q2 2021 Financials & Business Updates
August 10, 2021
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Tickers
JAGX
Jaguar Health Announces Adjournment of Annual Meeting of Stockholders Until Friday, September 3, 2021 and Encourages All Shareholders to Vote
August 06, 2021
From
Jaguar Health, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
Legal
Product Safety
Regulatory
Tickers
JAGX
REMINDER FROM JAGUAR HEALTH: Innovators with Jane King Interview with Lisa Conte to Air During Jaguar Investor Webcast on Thursday, July 29, 2021 at 8:30 AM Eastern to Provide Business Updates
July 28, 2021
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Tickers
JAGX
Jaguar Health Announces that Innovators with Jane King Interview with Lisa Conte will Air During Jaguar Investor Webcast on Thursday, July 29, 2021 at 8:30 AM Eastern to Provide Business Updates
July 26, 2021
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Tickers
JAGX
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 23, 2021
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Tickers
JAGX
Napo EU S.p.A., Jaguar Health's Italian Subsidiary, and Dragon SPAC S.p.A. Announce Close of 8,830,000 Euro Dragon SPAC Financing
July 19, 2021
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Tickers
JAGX
Jaguar Health Announces Completion of Investigator-Initiated Phase 2 HALT-D Study Evaluating Mytesi (Crofelemer) for Prevention and Prophylaxis of Diarrhea in Breast Cancer Patients
July 14, 2021
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Tickers
JAGX
Jaguar Health Announces Adjournment of Annual Meeting of Stockholders Until Friday, August 6, 2021 and Encourages All Shareholders to Vote
July 09, 2021
From
Jaguar Health, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
Legal
Product Safety
Regulatory
Tickers
JAGX
Jaguar Health Set to Join Russell Microcap Index
June 23, 2021
From
Jaguar Health, Inc.
Via
AccessWire
Topics
Derivatives
Exposures
Derivatives
Product Safety
Tickers
JAGX
Jaguar Health Announces Adjournment of Annual Meeting of Stockholders Until Friday, July 9, 2021 and Encourages All Shareholders to Vote
June 11, 2021
From
Jaguar Health, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
Legal
Product Safety
Regulatory
Tickers
JAGX
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 04, 2021
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Tickers
JAGX
REMINDER: Innovators with Jane King Webcast Interview with Jaguar Health CEO Lisa Conte & Dragon SPAC Founding Sponsor Josh Mailman to Take Place Thursday, June 3, 2021 at 8:30 AM Eastern
June 02, 2021
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Tickers
JAGX
Napo EU S.p.A., Jaguar Health’s Italian Subsidiary, Provides Updates on Plans to Pursue Conditional Marketing Authorization in the EU
June 01, 2021
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
COVID-19
Product Safety
Tickers
JAGX
Jaguar Health & Dragon SPAC Announce Initial Funding of US$10.8 Million into Dragon SPAC
June 01, 2021
From
Jaguar Health, Inc.
Via
AccessWire
Topics
Initial Public Offering
Exposures
Product Safety
Securities Market
Tickers
JAGX
Napo Pharmaceuticals, Jaguar Health’s Subsidiary, Bolsters Management Team with Appointment of Darlene Horton, M.D. as Chief Medical Officer
May 26, 2021
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Tickers
JAGX
Jaguar Health and Napo Pharmaceuticals Provide Key Findings from Cancer-related Diarrhea Abstracts Submitted to ASCO for June 2021 Annual Meeting
May 20, 2021
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Tickers
JAGX
Jaguar Health Announces the Launch of a New Social Media Channel Dedicated to Reaching the Growing Jaguar Health Community
May 19, 2021
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Tickers
JAGX
Jaguar Health Provides Updates on Canalevia (Crofelemer), the First Plant-based Prescription Medicine Under Development for Chemotherapy-induced Diarrhea in Dogs and Exercise-induced Diarrhea in Dogs
May 18, 2021
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Tickers
JAGX
Jaguar Health, Inc. Reports 2021 First Quarter Financial Results
May 17, 2021
From
Jaguar Health, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
COVID-19
Legal
Product Safety
Tickers
JAGX
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 14, 2021
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Tickers
JAGX
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.